alfapump System
Sequana Medical NV · Decision date Dec 19, 2025
What did the FDA approve?
FDA records P230044/S002 as a supplement to PMA P230044, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Dec 19, 2025.
FDA approval order statement
approval for a new mold release agent
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Dec 19, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P230044/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Sequana Medical NV
- Product code
- SDQ
- Decision code
- APPR
- Decision date
- Dec 19, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: alfapump System.
- Applicant
- Sequana Medical NV
- Product code
- SDQ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P230044/S002 received
Application receipt date recorded by FDA.
P230044/S002 · FDA decision
Real-Time Process
P230044/S003 · Related supplement
alfapump System
P230044/S004 · Related supplement
alfapump System
P230044/S005 · Related supplement
alfapump System
Timeline entries are records held by MedtechLedger for P230044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
alfapump SystemP230044/S003 | Sequana Medical NV | PMA supplement | Feb 18, 2026 | FDA |
alfapump SystemP230044/S004 | Sequana Medical NV | PMA supplement | May 5, 2026 | FDA |
alfapump SystemP230044/S005 | Sequana Medical NV | PMA supplement | May 5, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Sequana Medical NV
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Kortrijksesteweg 1112, Sint-Denijs-Westrem, 9051
Sources and methodology
- Original FDA record: P230044/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

